NCT03455387View on ClinicalTrials.gov

Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy.

CompletedOBSERVATIONAL

Enrollment

233

Participants

Timeline

Start Date

January 10, 2017

Primary Completion Date

December 20, 2019

Study Completion Date

December 31, 2019

Conditions

Pre-EclampsiaHELLP SyndromeFetal DeathEclampsiaPlacental AbruptionFetal Growth Retardation, Antenatal

Interventions

DIAGNOSTIC_TEST

sampling of the serum marker sFlt1 and PlGF

sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery

Trial Locations (7)

29200

CHU de Brest, Brest

73000

CHMetropoleSavoie, Chambéry

74130

Centre Hospitalier Alpes Léman, Contamine-sur-Arve

74200

Hôpitaux du Léman, Thonon-les-Bains

74370

Centre Hospitalier Annecy Genevois, Metz-Tessy

76083

Groupe Hospitalier du Havre, Le Havre

87042

CHU de Limoges, Limoges

All Listed Sponsors

lead

Centre Hospitalier Metropole Savoie

OTHER

NCT03455387 - Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy. | Biotech Hunter | Biotech Hunter